Physician profile
Amanda Boyd
NPI 1447640321
$10,107.16
in general payments reported to CMS, 2019-2025
30 companies · $3,068 in 2025
The $3,068 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,206 · 2022: $1,450 · 2023: $2,495 · 2024: $1,888 · 2025: $3,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,144 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,143.97 |
| Education | $307.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,499.69 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,444.69 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,131.32 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $962.69 | 2021-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $923.13 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $836.76 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $484.66 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $446.80 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $375.72 | 2023-2025 | Auvelity |
| Corium, LLC | $363.74 | 2022-2025 | Azstarys |
| Lundbeck LLC | $210.81 | 2021-2025 | Rexulti |
| Neos Therapeutics, LP | $206.15 | 2021-2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $199.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $196.64 | 2023-2025 | Spravato |
| Almatica Pharma LLC | $165.30 | 2022-2024 | Loreev Xr, Sertraline Hcl |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $150.17 | 2021-2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $86.49 | 2025 | Cobenfy |
| Bausch Health US, LLC | $75.89 | 2021-2023 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $67.07 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $63.65 | 2025 | Spravato |
| Eisai INC. | $41.95 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.95 | 2025 | Rejoyn |
| Noven Therapeutics, LLC | $24.75 | 2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $20.05 | 2022 | |
| Tris Pharma INC | $19.96 | 2024 | Dyanavel Xr |
| Genentech USA, INC. | $19.50 | 2025 | Polivy |
| Spectrum Pharmaceuticals INC. | $16.12 | 2025 | Rolvedon |
| Ironshore Pharmaceuticals INC. | $15.87 | 2021 | |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
| Adlon Therapeutics L.P. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.